Finance

Lists
CBIO:NASDAQ
Crescent Biopharma Inc
၁၂.၈၁ US$
-၀.၇၆%
(-၀.၀၉၈) 1D
အောက် ၁၄, GMT-၄ ၁၂:၀၇:၃၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
၁၂.၆၇ US$
High
၁၃.၂၁ US$
Low
၁၂.၁၈ US$
Mkt. cap
၄၇.၆၉ ကုဋေ
Avg. vol.
၅.၀၄ သိန်း
Volume
၈.၀၇ သောင်း
52-wk high
၂၇.၄၁ US$
52-wk low
၈.၇၂ US$
EPS
-၇.၄၁ US$
Beta
၁.၂၇
Shares outstanding
၃.၇၁ ကုဋေ
No. of employees
၆၉
Open
၁၂.၆၇ US$
High
၁၃.၂၁ US$
Low
၁၂.၁၈ US$
Mkt. cap
၄၇.၆၉ ကုဋေ
Avg. vol.
၅.၀၄ သိန်း
Volume
၈.၀၇ သောင်း
52-wk high
၂၇.၄၁ US$
52-wk low
၈.၇၂ US$
EPS
-၇.၄၁ US$
Beta
၁.၂၇
Shares outstanding
၃.၇၁ ကုဋေ
No. of employees
၆၉
News stories
From web sources and news partners
Investing News Network
Investing News Network
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
The Arkansas Democrat-Gazette
The Arkansas Democrat-Gazette
·
ပြီးခဲ့သည့် ၂၄ မိနစ်
Little Rock based BSR Real Estate Investment Trust shares trading on the New York Stock Exchange
Reuters
Reuters
·
ပြီးခဲ့သည့် ၂ နာရီ
Wall St opens lower after hot CPI data fuels rate-hike bets
About Crescent Biopharma Inc
CEO-
Employees၆၉
Founded၂၀၂၄
HeadquartersWaltham, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current ၁၂.၈၁ US$
၃၆.၀၀ US$ (+၁၈၀.၉၈%)
Average
၂၉.၇၅ US$ (+၁၃၂.၂၀%)
Lowest
၂၇.၀၀ US$ (+၁၁၀.၇၃%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
၂၈.၀၀ US$
+၁၁၈.၅%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
၃၆.၀၀ US$
+၁၈၁%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
၂၈.၀၀ US$
+၁၁၈.၅%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
၂၇.၀၀ US$
+၁၁၀.၇%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
၂၇.၀၀ US$
+၁၁၀.၇%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
၃၅.၀၀ US$
+၁၇၃.၂%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
၃၅.၀၀ US$
+၁၇၃.၂%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
၁.၀၈ ကုဋေ
၁.၀၄ သန်း
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၂.၀၃ ကုဋေ
၉.၅၀ ကုဋေ
၁.၇၉ ကုဋေ
၁.၉၄ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၅.၅၄ သန်း
၇.၃၁ သန်း
၇.၈၆ သန်း
၈.၇၄ သန်း
Operating expense
၂.၅၉ ကုဋေ
၁၀.၂၃ ကုဋေ
၂.၅၈ ကုဋေ
၂.၈၁ ကုဋေ
Total operating expenses
၂.၅၉ ကုဋေ
၁၀.၂၃ ကုဋေ
၂.၅၈ ကုဋေ
၂.၈၁ ကုဋေ
Operating income
-၂.၅၉ ကုဋေ
-၉.၁၅ ကုဋေ
-၂.၄၇ ကုဋေ
-၂.၈၁ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၂.၄၆ ကုဋေ
-၉.၀၄ ကုဋေ
-၂.၃၃ ကုဋေ
-၂.၄၈ ကုဋေ
EBT excluding unusual items
-၂.၄၆ ကုဋေ
-၉.၀၄ ကုဋေ
-၂.၃၃ ကုဋေ
-၂.၆၆ ကုဋေ
Income tax expense
-
၂.၀၀ သန်း
-
-
Effective tax rate
-
-၂.၂၁%
-
-
Other operating expenses
-
-
-
-
Net income
-၂.၄၆ ကုဋေ
-၉.၂၄ ကုဋေ
-၂.၃၃ ကုဋေ
-၂.၄၈ ကုဋေ
Net profit margin
-
-၈၅၂.၀၆%
-၂,၂၄၀.၉၀%
-
Earnings per share
-၁.၃၇
-၄.၉၂
-၀.၇၀
-၀.၆၂
Interest and investment income
၁.၂၈ သန်း
၁.၁၀ သန်း
၁.၄၅ သန်း
၁.၅၃ သန်း
Interest expense
-
-
-
-
Net interest expenses
၁.၂၈ သန်း
၁.၁၀ သန်း
၁.၄၅ သန်း
၁.၅၃ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၅၉ ကုဋေ
-၉.၁၄ ကုဋေ
-၂.၄၇ ကုဋေ
-၂.၈၁ ကုဋေ
Gain or loss from assets sale
-
-
-
-၁.၇၇ သန်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ